Revised International Prognostic Index (R-IPI) Calculator

Risk-stratifies patients with diffuse large B-cell lymphoma treated with rituximab-based therapy. Includes interpretation, information buttons and a clinical guide.

Sponsored
Advertising placement
Revised International Prognostic Index (R-IPI)
Clinical Decision Tool

Risk-stratifies patients with diffuse large B-cell lymphoma treated with rituximab-based therapy.

Select the finding that best matches the patient.
Select the finding that best matches the patient.
Select the finding that best matches the patient.
Select the finding that best matches the patient.
Select the finding that best matches the patient.
Log in to save Save this calculator to your MediCalc account.

Log in to save incomplete calculator progress and return later.

Clinical Decision Support Only

MediCalc calculators are intended to support qualified healthcare professionals and must not replace professional clinical judgement. Do not enter patient-identifiable information into Saved Progress.

Read our Clinical Disclaimer
MedicalC Knowledge Hub

Revised International Prognostic Index (R-IPI): Clinical Guide

Browse Knowledge Hub

Risk-stratifies patients with diffuse large B-cell lymphoma treated with rituximab-based therapy.

Overview

Risk-stratifies patients with diffuse large B-cell lymphoma treated with rituximab-based therapy.

Clinical Significance

R-IPI uses the five original IPI adverse factors and reports three prognostic groups.

When to Use

  • Use as structured clinical decision support when the required data are available and reliable.

How It Is Calculated

  • The displayed variables are combined using the published equation, decision rule or weighted point system.

Interpretation

  • R-IPI uses the five original IPI adverse factors and reports three prognostic groups.

Worked Example

Enter verified patient data in the displayed units; MedicalC applies the published model.

Limitations

  • Risk and classification tools can be misapplied outside their validated population.
  • Missing, estimated or non-contemporaneous data may materially change the result.

Clinical Pearls

  • Document the inputs, units, date and clinical setting with the result.
  • Use serial scores only when the same instrument and measurement method are used consistently.

Common Mistakes

  • Using the tool without confirming entry criteria.
  • Using approximate or incorrectly converted values.
  • Treating a prognostic score as a standalone treatment decision.

Frequently Asked Questions

What does this tool calculate?

Risk-stratifies patients with diffuse large B-cell lymphoma treated with rituximab-based therapy.

Can this result be used alone?

No. Interpret it with the full clinical assessment, applicable entry criteria and current guidance.

References

  1. Sehn LH et al. Blood. 2007;109:1857-1861. — Primary or supporting reference for the implemented model.

Reviewed by: MedicalC Clinical Editorial Team
Last reviewed: July 2026

Return to calculator

Reviewed by: MedicalC Clinical Editorial Team Last reviewed: July 2026

Clinical Disclaimer

MedicalC calculators and clinical tools are intended to support healthcare professionals. They do not replace clinical judgement, individual patient assessment, local guidance or specialist advice.

Results should always be interpreted in the context of the patient’s history, examination, investigations, current clinical condition and applicable professional guidance.

Reviewed by: MedicalC Clinical Editorial Team Last reviewed: July 2026
Sponsored
Advertising placement